{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-003686","form_type":"8-K/A","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.548842+00:00","generated_at":"2026-06-20T19:03:08.633289+00:00","sec_items":["5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TherapeuticsMD closes Mayne Pharma license deal, appoints new CEO, reports pro forma loss","bullets":["On Dec 30, 2022, terminated co-CEOs Brian Bernick and Mark Glickman; Glickman eligible for $100k consulting fee plus performance bonuses.","On Jan 4, 2023, appointed General Counsel Marlan Walker as CEO and Principal Executive Officer.","Mayne Pharma paid $140M upfront for licenses and assets; plus ~$12.1M for working capital and $1M prepaid royalties.","Pro forma 2021 net loss of $7.0M, 9mo 2022 net loss of $6.6M; balance sheet shows debt eliminated, cash of ~$128M post-transaction.","Royalty stream includes 8% on first $80M annual sales, minimum $3M/year for 12 years, and milestone payments up to $30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-003686","json":"https://secwatch.observer/filing/0001193125-23-003686.json","markdown":"https://secwatch.observer/filing/0001193125-23-003686.md","text":"https://secwatch.observer/filing/0001193125-23-003686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/d389338d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:03:08.633289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31403f1ee3","claim":"Marlan Walker was appointed as Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6624d17a67","claim":"Mark Glickman was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Interim Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b4006d6510","claim":"Brian Bernick was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..","evidence_excerpt":"On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Interim Co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}